Advertisement
Screener

CORCEPT THERAPEUTICS INC (CORT) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

CORCEPT THERAPEUTICS INC Selling, General and Administrative Expense

CORCEPT THERAPEUTICS INC (CORT) reported Selling, General and Administrative Expense of $156.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-29

  • CORCEPT THERAPEUTICS INC selling, general and administrative expense for the quarter ending 2026-06-30 was $156.90M, a 51.08% increase year-over-year.
  • CORCEPT THERAPEUTICS INC selling, general and administrative expense for the quarter ending 2026-03-31 was $145.36M, a 60.33% increase year-over-year.
  • CORCEPT THERAPEUTICS INC selling, general and administrative expense for the quarter ending 2025-12-31 was $130.24M, a 56.21% increase year-over-year.
  • CORCEPT THERAPEUTICS INC selling, general and administrative expense for the quarter ending 2025-09-30 was $123.98M, a 68.12% increase year-over-year.
  • CORCEPT THERAPEUTICS INC selling, general and administrative expense for fiscal 2025 was $448.73M, a 60.08% increase from fiscal 2024.
  • CORCEPT THERAPEUTICS INC selling, general and administrative expense for fiscal 2024 was $280.32M, a 52.13% increase from fiscal 2023.
  • CORCEPT THERAPEUTICS INC selling, general and administrative expense for fiscal 2023 was $184.26M, a 20.55% increase from fiscal 2022.
  • CORCEPT THERAPEUTICS INC selling, general and administrative expense for fiscal 2022 was $152.85M, a 24.92% increase from fiscal 2021.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 12 monthSelling, General and Administrative Expense 167 month
2026-06-30$156.90M
10-Q · filed 2026-07-29
$302.25M
10-Q · filed 2026-07-29
$432.49M
derived: sum of 3 quarters · filed 2026-07-29
$556.47M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$145.36M
10-Q · filed 2026-04-30
$275.59M
derived: sum of 2 quarters · filed 2026-04-30
$399.57M
derived: sum of 3 quarters · filed 2026-04-30
$503.42M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31$130.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$254.21M
derived: sum of 2 quarters · filed 2026-02-24
$358.06M
derived: sum of 3 quarters · filed 2026-07-29
$448.73M
10-K · filed 2026-02-24
2025-09-30$123.98M
10-Q · filed 2025-11-04
$227.83M
derived: sum of 2 quarters · filed 2026-07-29
$318.49M
10-Q · filed 2025-11-04
$401.86M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$103.85M
10-Q · filed 2026-07-29
$194.51M
10-Q · filed 2026-07-29
$277.88M
derived: sum of 3 quarters · filed 2026-07-29
$351.63M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31$90.66M
10-Q · filed 2026-04-30
$174.03M
derived: sum of 2 quarters · filed 2026-04-30
$247.78M
derived: sum of 3 quarters · filed 2026-04-30
$314.71M
derived: sum of 4 quarters · filed 2026-04-30
2024-12-31$83.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$157.12M
derived: sum of 2 quarters · filed 2026-02-24
$224.05M
derived: sum of 3 quarters · filed 2026-02-24
$280.32M
10-K · filed 2026-02-24
2024-09-30$73.75M
10-Q · filed 2025-11-04
$140.68M
derived: sum of 2 quarters · filed 2025-11-04
$196.95M
10-Q · filed 2025-11-04
$244.10M
derived: sum of 4 quarters · filed 2026-02-24
2024-06-30$66.94M
10-Q · filed 2025-07-31
$123.20M
10-Q · filed 2025-07-31
$170.35M
derived: sum of 3 quarters · filed 2026-02-24
$215.62M
derived: sum of 4 quarters · filed 2026-02-24
2024-03-31$56.27M
10-Q · filed 2025-05-05
$103.42M
derived: sum of 2 quarters · filed 2026-02-24
$148.68M
derived: sum of 3 quarters · filed 2026-02-24
$191.96M
derived: sum of 4 quarters · filed 2026-02-24
2023-12-31$47.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
$92.41M
derived: sum of 2 quarters · filed 2026-02-24
$135.69M
derived: sum of 3 quarters · filed 2026-02-24
$184.26M
10-K · filed 2026-02-24
2023-09-30$45.26M
10-Q · filed 2024-10-30
$88.54M
derived: sum of 2 quarters · filed 2024-10-30
$137.11M
10-Q · filed 2024-10-30
$179.43M
derived: sum of 4 quarters · filed 2025-02-26
2023-06-30$43.28M
10-Q · filed 2024-07-29
$91.84M
10-Q · filed 2024-07-29
$134.17M
derived: sum of 3 quarters · filed 2025-02-26
$169.33M
derived: sum of 4 quarters · filed 2025-02-26
2023-03-31$48.56M
10-Q · filed 2024-05-01
$90.89M
derived: sum of 2 quarters · filed 2025-02-26
$126.05M
derived: sum of 3 quarters · filed 2025-02-26
$163.86M
derived: sum of 4 quarters · filed 2025-02-26
2022-12-31$42.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26
$77.49M
derived: sum of 2 quarters · filed 2025-02-26
$115.30M
derived: sum of 3 quarters · filed 2025-02-26
$152.85M
10-K · filed 2025-02-26
2022-09-30$35.16M
10-Q · filed 2023-11-01
$72.98M
derived: sum of 2 quarters · filed 2023-11-01
$110.53M
10-Q · filed 2023-11-01
$142.81M
derived: sum of 4 quarters · filed 2024-02-15
2022-06-30$37.81M
10-Q · filed 2023-08-02
$75.36M
10-Q · filed 2023-08-02
$107.65M
derived: sum of 3 quarters · filed 2024-02-15
$138.18M
derived: sum of 4 quarters · filed 2024-02-15
2022-03-31$37.55M
10-Q · filed 2023-05-03
$69.83M
derived: sum of 2 quarters · filed 2024-02-15
$100.37M
derived: sum of 3 quarters · filed 2024-02-15
$130.40M
derived: sum of 4 quarters · filed 2024-02-15
2021-12-31$32.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15
$62.82M
derived: sum of 2 quarters · filed 2024-02-15
$92.85M
derived: sum of 3 quarters · filed 2024-02-15
$122.36M
10-K · filed 2024-02-15
2021-09-30$30.53M
10-Q · filed 2022-11-03
$60.56M
derived: sum of 2 quarters · filed 2022-11-03
$90.07M
10-Q · filed 2022-11-03
$115.77M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30$30.03M
10-Q · filed 2022-08-04
$59.54M
10-Q · filed 2022-08-04
$85.23M
derived: sum of 3 quarters · filed 2023-02-28
$111.76M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31$29.51M
10-Q · filed 2022-05-05
$55.20M
derived: sum of 2 quarters · filed 2023-02-28
$81.73M
derived: sum of 3 quarters · filed 2023-02-28
$107.30M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31$25.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
$52.22M
derived: sum of 2 quarters · filed 2023-02-28
$77.79M
derived: sum of 3 quarters · filed 2023-02-28
$105.33M
10-K · filed 2023-02-28
2020-09-30$26.52M
10-Q · filed 2021-11-03
$52.09M
derived: sum of 2 quarters · filed 2021-11-03
$79.63M
10-Q · filed 2021-11-03
$106.76M
derived: sum of 4 quarters · filed 2022-02-15
2020-06-30$25.57M
10-Q · filed 2021-07-29
$53.11M
10-Q · filed 2021-07-29
$80.24M
derived: sum of 3 quarters · filed 2022-02-15
$104.48M
derived: sum of 4 quarters · filed 2022-02-15
2020-03-31$27.54M
10-Q · filed 2021-05-06
$54.67M
derived: sum of 2 quarters · filed 2022-02-15
$78.91M
derived: sum of 3 quarters · filed 2022-02-15
$103.50M
derived: sum of 4 quarters · filed 2022-02-15
2019-12-31$27.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15
$51.38M
derived: sum of 2 quarters · filed 2022-02-15
$75.97M
derived: sum of 3 quarters · filed 2022-02-15
$100.36M
10-K · filed 2022-02-15
2019-09-30$24.25M
10-Q · filed 2020-11-03
$48.84M
derived: sum of 2 quarters · filed 2020-11-03
$73.23M
10-Q · filed 2020-11-03
$94.78M
derived: sum of 4 quarters · filed 2021-02-23
2019-06-30$24.59M
10-Q · filed 2020-08-04
$48.98M
10-Q · filed 2020-08-04
$70.54M
derived: sum of 3 quarters · filed 2021-02-23
$91.85M
derived: sum of 4 quarters · filed 2021-02-23
2019-03-31$24.39M
10-Q · filed 2020-05-04
$45.95M
derived: sum of 2 quarters · filed 2021-02-23
$67.26M
derived: sum of 3 quarters · filed 2021-02-23
$87.24M
derived: sum of 4 quarters · filed 2021-02-23
2018-12-31$21.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23
$42.87M
derived: sum of 2 quarters · filed 2021-02-23
$62.85M
derived: sum of 3 quarters · filed 2021-02-23
$81.29M
10-K · filed 2021-02-23
2018-09-30$21.31M
10-Q · filed 2019-11-07
$41.29M
derived: sum of 2 quarters · filed 2019-11-07
$59.73M
10-Q · filed 2019-11-07
$76.52M
derived: sum of 4 quarters · filed 2020-02-24
2018-06-30$19.98M
10-Q · filed 2019-08-01
$38.42M
10-Q · filed 2019-08-01
$55.22M
derived: sum of 3 quarters · filed 2020-02-24
$71.69M
derived: sum of 4 quarters · filed 2020-02-24
2018-03-31$18.44M
10-Q · filed 2019-05-09
$35.23M
derived: sum of 2 quarters · filed 2020-02-24
$51.71M
derived: sum of 3 quarters · filed 2020-02-24
$65.82M
derived: sum of 4 quarters · filed 2020-02-24
2017-12-31$16.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24
$33.27M
derived: sum of 2 quarters · filed 2020-02-24
$47.38M
derived: sum of 3 quarters · filed 2020-02-24
$62.42M
10-K · filed 2020-02-24
2017-09-30$16.47M
10-Q · filed 2018-11-02
$30.58M
derived: sum of 2 quarters · filed 2018-11-02
$45.62M
10-Q · filed 2018-11-02
$57.38M
derived: sum of 4 quarters · filed 2019-02-26
2017-06-30$14.11M
10-Q · filed 2018-08-09
$29.15M
10-Q · filed 2018-08-09
$40.91M
derived: sum of 3 quarters · filed 2019-02-26
$51.84M
derived: sum of 4 quarters · filed 2019-02-26
2017-03-31$15.04M
10-Q · filed 2018-05-09
$26.80M
derived: sum of 2 quarters · filed 2019-02-26
$37.73M
derived: sum of 3 quarters · filed 2019-02-26
$49.85M
derived: sum of 4 quarters · filed 2019-02-26
2016-12-31$11.76M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26
$22.69M
derived: sum of 2 quarters · filed 2019-02-26
$34.81M
derived: sum of 3 quarters · filed 2019-02-26
$45.24M
10-K · filed 2019-02-26
2016-09-30$10.93M
10-Q · filed 2017-11-03
$23.05M
derived: sum of 2 quarters · filed 2017-11-03
$33.48M
10-Q · filed 2017-11-03
$42.34M
derived: sum of 4 quarters · filed 2018-02-28
2016-06-30$12.12M
10-Q · filed 2017-08-02
$22.55M
10-Q · filed 2017-08-02
$31.41M
derived: sum of 3 quarters · filed 2018-02-28
$40.70M
derived: sum of 4 quarters · filed 2018-02-28
2016-03-31$10.43M
10-Q · filed 2017-05-02
$19.30M
derived: sum of 2 quarters · filed 2018-02-28
$28.59M
derived: sum of 3 quarters · filed 2018-02-28
$37.93M
derived: sum of 4 quarters · filed 2018-02-28
2015-12-31$8.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28
$18.15M
derived: sum of 2 quarters · filed 2018-02-28
$27.50M
derived: sum of 3 quarters · filed 2018-02-28
$36.95M
10-K · filed 2018-02-28
2015-09-30$9.29M
10-Q · filed 2016-11-02
$18.63M
derived: sum of 2 quarters · filed 2016-11-02
$28.09M
10-Q · filed 2016-11-02
$36.13M
derived: sum of 4 quarters · filed 2017-03-06
2015-06-30$9.34M
10-Q · filed 2016-08-03
$18.80M
10-Q · filed 2016-08-03
$26.84M
derived: sum of 3 quarters · filed 2017-03-06
$35.94M
derived: sum of 4 quarters · filed 2017-03-06
2015-03-31$9.45M
10-Q · filed 2016-05-04
$17.50M
derived: sum of 2 quarters · filed 2017-03-06
$26.60M
derived: sum of 3 quarters · filed 2017-03-06
$34.56M
derived: sum of 4 quarters · filed 2017-03-06
2014-12-31$8.04M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06
$17.15M
derived: sum of 2 quarters · filed 2017-03-06
$25.11M
derived: sum of 3 quarters · filed 2017-03-06
$34.92M
10-K · filed 2017-03-06
2014-09-30$9.10M
10-Q · filed 2015-11-06
$17.07M
derived: sum of 2 quarters · filed 2015-11-06
$26.87M
10-Q · filed 2015-11-06
$34.39M
derived: sum of 4 quarters · filed 2016-03-10
2014-06-30$7.96M
10-Q · filed 2015-08-07
$17.77M
10-Q · filed 2015-08-07
$25.29M
derived: sum of 3 quarters · filed 2016-03-10
$32.47M
derived: sum of 4 quarters · filed 2016-03-10
2014-03-31$9.80M
10-Q · filed 2015-05-08
$17.32M
derived: sum of 2 quarters · filed 2016-03-10
$24.50M
derived: sum of 3 quarters · filed 2016-03-10
$32.66M
derived: sum of 4 quarters · filed 2016-03-10
2013-12-31$7.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10
$14.70M
derived: sum of 2 quarters · filed 2016-03-10
$22.86M
derived: sum of 3 quarters · filed 2016-03-10
$31.24M
10-K · filed 2016-03-10
2013-09-30$7.18M
10-Q · filed 2014-11-07
$15.34M
derived: sum of 2 quarters · filed 2014-11-07
$23.72M
10-Q · filed 2014-11-07
$30.20M
derived: sum of 4 quarters · filed 2015-03-13
2013-06-30$8.16M
10-Q · filed 2014-08-08
$16.54M
10-Q · filed 2014-08-08
$23.02M
derived: sum of 3 quarters · filed 2015-03-13
$28.72M
derived: sum of 4 quarters · filed 2015-03-13
2013-03-31$8.38M
10-Q · filed 2014-05-12
$14.87M
derived: sum of 2 quarters · filed 2015-03-13
$20.56M
derived: sum of 3 quarters · filed 2015-03-13
$26.31M
derived: sum of 4 quarters · filed 2015-03-13
2012-12-31$6.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13
$12.18M
derived: sum of 2 quarters · filed 2015-03-13
$17.93M
derived: sum of 3 quarters · filed 2015-03-13
$25.41M
10-K · filed 2015-03-13
2012-09-30$5.69M
10-Q · filed 2013-11-12
$11.45M
derived: sum of 2 quarters · filed 2013-11-12
$18.93M
10-Q · filed 2013-11-12
$22.21M
derived: sum of 4 quarters · filed 2014-03-14
2012-06-30$5.75M
10-Q · filed 2013-08-09
$13.24M
10-Q · filed 2013-08-09
$16.52M
derived: sum of 3 quarters · filed 2014-03-14
$19.73M
derived: sum of 4 quarters · filed 2014-03-14
2012-03-31$7.49M
10-Q · filed 2013-05-08
$10.77M
derived: sum of 2 quarters · filed 2014-03-14
$13.98M
derived: sum of 3 quarters · filed 2014-03-14
$16.64M
derived: sum of 4 quarters · filed 2014-03-14
$68.07M
10-Q · filed 2012-05-10
2011-12-31$3.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14
$6.49M
derived: sum of 2 quarters · filed 2014-03-14
$9.16M
derived: sum of 3 quarters · filed 2014-03-14
$11.33M
10-K · filed 2014-03-14
2011-09-30$3.21M
10-Q · filed 2012-11-08
$5.88M
derived: sum of 2 quarters · filed 2012-11-08
$8.05M
10-Q · filed 2012-11-08
2011-06-30$2.67M
10-Q · filed 2012-08-09
$4.84M
10-Q · filed 2012-08-09
2011-03-31$2.17M
10-Q · filed 2012-05-10
2010-12-31$8.49M
10-K · filed 2013-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52